Ultragenyx Pharmaceutical (RARE) News Today $28.11 +0.72 (+2.63%) Closing price 04:00 PM EasternExtended Trading$28.30 +0.20 (+0.69%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Knott David M Jr Takes $1.74 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)August 12 at 8:17 AM | marketbeat.comMotley Fool Asset Management LLC Grows Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)August 12 at 7:13 AM | marketbeat.comNatixis Advisors LLC Sells 27,404 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)August 12 at 3:36 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 11 at 10:00 AM | prnewswire.comMereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143August 11 at 8:05 AM | msn.comCanaccord Genuity Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceAugust 11 at 3:51 AM | americanbankingnews.comEquities Analysts Issue Forecasts for RARE Q3 EarningsAugust 11 at 2:43 AM | marketbeat.comCanaccord Genuity Group Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceAugust 10 at 5:58 PM | marketbeat.comHC Wainwright Issues Optimistic Forecast for RARE EarningsAugust 10 at 2:31 AM | americanbankingnews.comWhat is William Blair's Estimate for RARE Q3 Earnings?August 10 at 2:31 AM | americanbankingnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Ultragenyx Pharmaceutical (RARE) and MoonLake Immunotherapeutics (MLTX)August 9 at 9:09 PM | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 9 at 12:25 PM | globenewswire.comWhat is Wedbush's Estimate for RARE FY2028 Earnings?August 9 at 11:44 AM | marketbeat.comCantor Fitzgerald Brokers Cut Earnings Estimates for RAREAugust 9 at 9:28 AM | marketbeat.comHC Wainwright Issues Positive Estimate for RARE EarningsAugust 9 at 8:09 AM | marketbeat.comLeerink Partnrs Has Positive Estimate for RARE Q3 EarningsAugust 9 at 8:09 AM | marketbeat.comWhat is William Blair's Forecast for RARE Q3 Earnings?August 9 at 8:09 AM | marketbeat.comCantor Fitzgerald Issues Negative Outlook for RARE EarningsAugust 9 at 3:19 AM | americanbankingnews.comUltragenyx (RARE) Q2 Revenue Up 13%August 9 at 2:46 AM | theglobeandmail.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?August 9 at 2:46 AM | finance.yahoo.comLeerink Partnrs Has Positive Outlook of RARE Q3 EarningsAugust 9 at 2:25 AM | americanbankingnews.comWilliam Blair Brokers Lower Earnings Estimates for RAREAugust 8, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for RARE Q1 Earnings?August 8, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Given New $105.00 Price Target at Cantor FitzgeraldAugust 7, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | msn.com2RARE : 8 Analysts Assess Ultragenyx Pharmaceutical: What You Need To KnowAugust 6, 2025 | benzinga.comUltragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPSAugust 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 6, 2025 | prnewswire.comUltragenyx Completes Enrollment for GTX-102 Phase 3 StudyAugust 6, 2025 | theglobeandmail.comUltragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comUltragenyx Reports Second Quarter 2025 Financial Results and Corporate UpdateAugust 5, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (RARE): A Bull Case TheoryAugust 4, 2025 | insidermonkey.comWhat to Expect from Ultragenyx Pharmaceutical's EarningsAugust 4, 2025 | benzinga.comXTX Topco Ltd Raises Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)August 3, 2025 | marketbeat.comTD Asset Management Inc Buys 45,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)August 3, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of "Moderate Buy" by AnalystsAugust 2, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick ResubmissionJuly 31, 2025 | finance.yahoo.comUltragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick ResubmissionJuly 31, 2025 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 31, 2025 | prnewswire.comQ2 Earnings Estimate for RARE Issued By HC WainwrightJuly 31, 2025 | marketbeat.comUltragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate UpdateJuly 30, 2025 | globenewswire.com43,274 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by GSA Capital Partners LLPJuly 30, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Invests $1.18 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)July 30, 2025 | marketbeat.comUltragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 CatalystJuly 29, 2025 | seekingalpha.com3RARE : Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical StockJuly 28, 2025 | benzinga.comUltragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent SetbacksJuly 28, 2025 | benzinga.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 22, 2025 | prnewswire.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼0.230.75▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼5610▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Viatris News BridgeBio Pharma News Verona Pharma PLC American Depositary Share News Blueprint Medicines News Roivant Sciences News Grifols News Legend Biotech News Elanco Animal Health News Revolution Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access